Our services: capital raising for fast growing companies

AGIO Capital
eTheRNA is a clinical-stage mRNA companies in the European healthcare sector. The company has mRNA technology discovery and development capabilities with a full platform of integrated capabilities, including own manufacturing. As the company’s current investors were already mostly the European Tier-I healthcare investors,  the company wanted to attract new investors for their € 39M Series B, and at the same gain access to the Asian market. What we did and delivered
    • Given the company’s global cutting-edge technology and great opportunities globally, eTheRNA had a competitive advantage in China.  Partnering with Chinese pharma companies was the best way forward to gain access to the Chinese market
    • We successfully brought in a Chinese strategic lead investor & two follow investors for the €39M Series B
    • We brokered the Licensing & Joint Venture deal with Grand Pharma (0512.HK)
    • eTheRNA completed its Series B and later on its Series C
    • Via its Joint Venture in China the company has now manufacturing and product development capabilities, important to launch its products locally 

Our specialists in the field